| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/06/2006 | DE102004061751A1 Cyanoguanidin-substituierte Pyrazoline Cyanoguanidino substituted pyrazolines |
| 07/06/2006 | DE102004061750A1 Heteroaryl-substituierte Pyrazoline Heteroaryl substituted pyrazolines |
| 07/06/2006 | DE102004061748A1 Azetidin-substituierte Pyrazoline Azetidine-substituted pyrazolines |
| 07/06/2006 | DE102004061747A1 Thiophen-substituierte Pyrazoline Thiophene-substituted pyrazolines |
| 07/06/2006 | DE102004061746A1 Alkinyl-substituierte Thiophene Alkynyl-substituted thiophenes |
| 07/06/2006 | DE102004060914A1 Verwendung von Liponsäure-haltigen Cyclodextrin-Komplexen Use of lipoic acid-containing cyclodextrin complexes |
| 07/06/2006 | DE102004060542A1 Hydroxybiphenyl-Carbonsäuren und Derivate, Verfahren zu deren Herstellung und deren Verwendung Hydroxybiphenyl-carboxylic acids and derivatives, processes for their preparation and their use |
| 07/06/2006 | DE102004060412A1 New isopropanol and water mixed solvate of olanzapine used to prepare any other solvate and/or hydrate forms of olanzapine, or anhydrous forms of olanzapine |
| 07/06/2006 | DE102004060246A1 Verwendung von Chitosan gegen Juckreiz Use of chitosan for itching |
| 07/06/2006 | DE102004025726B4 Verwendung eines spezifischen K252a-Derivats zur Verhinderung oder Behandlung der Alzheimerschen Krankheit Using a specific K252a derivative for the prevention or treatment of Alzheimer's disease |
| 07/06/2006 | DE102004014841B4 Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms Use of rotigotine for the treatment and prevention of Parkinson's plus syndrome |
| 07/06/2006 | CA2594676A1 Thienopyrimidine derivatives as phosphodiesterase 10 inhibitors |
| 07/06/2006 | CA2594345A1 Compositions and methods of treating cell proliferation disorders |
| 07/06/2006 | CA2594325A1 Condensed imidazole compound and use thereof |
| 07/06/2006 | CA2594320A1 Method for producing l-biopterin |
| 07/06/2006 | CA2594280A1 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists |
| 07/06/2006 | CA2594251A1 Pyrrolidyl derivatives of heteroaromatic compounds as phosphodiesterase inhibitors |
| 07/06/2006 | CA2594241A1 Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for medical treatment |
| 07/06/2006 | CA2594229A1 2',3'-dideoxy-3'-c-hyroxymethylcytidine and prodrugs thereof for the treatment of drug escape mutant hiv |
| 07/06/2006 | CA2594212A1 Cardiovascular compositions |
| 07/06/2006 | CA2594203A1 Use of a vanilloid receptor agonist together with a glycosaminoglycan or proteoglycan for producing an agent for treating articular pain and method for applying said agent |
| 07/06/2006 | CA2594202A1 Use of resiniferatoxin (rtx) for producing an agent for treating joint pains and method for applying said agent |
| 07/06/2006 | CA2594155A1 A process for producing a food or beverage |
| 07/06/2006 | CA2593993A1 Pyrazole compounds that modulate the activity of cdk, gsk and aurora kinases |
| 07/06/2006 | CA2593862A1 Nanoparticle composition and methods for synthesis thereof |
| 07/06/2006 | CA2593064A1 Hyaluronic acid linked with a polymer of an alpha hydroxy acid |
| 07/06/2006 | CA2593035A1 Pharmaceutical compositions for treating diseases associated with nf-.kappa.b activity |
| 07/06/2006 | CA2592898A1 Polymorphs of 1-(2-methylpropyl)-1h-imidazo[4,5-c][1,5]naphthyridin-4-amine ethanesulfonate |
| 07/06/2006 | CA2592858A1 Substituted indazolyl sulfonamide and 2,3-dihydro-indolyl sulfonamide compounds, their preparation and use in medicaments |
| 07/06/2006 | CA2592852A1 Nitro-substituted phenyl-piperazine compounds, their preparation and use in medicaments |
| 07/06/2006 | CA2592832A1 Substituted phenyl-piperazine compounds, their preparation and use in medicaments |
| 07/06/2006 | CA2592532A1 Sesamin/episesamin compositions with improved bioavailability |
| 07/06/2006 | CA2592514A1 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| 07/06/2006 | CA2592509A1 Benzazole analogues and uses thereof |
| 07/06/2006 | CA2592461A1 Drugs for diseases accompanying changes in total bile acid pool or lipid metabolism disorders and method of screening these drugs |
| 07/06/2006 | CA2592287A1 Complex formulation of 3-hydroxy-3-methyl glutaryl coa reductase inhibitor and antihypertensive agent, and process for preparing same |
| 07/06/2006 | CA2592279A1 Quercetin glycoside composition and method of preparing the same |
| 07/06/2006 | CA2592278A1 Use of cgrp antagonists in treatment and prevention of hot flushes in prostate cancer patients |
| 07/06/2006 | CA2592131A1 Substituted pyrrolidinones having an antithrombotic effect, the production thereof and their use as medicaments |
| 07/06/2006 | CA2592021A1 Fluorescent pyrazine derivatives and methods of using the same in assessing renal function |
| 07/06/2006 | CA2591912A1 Pyrimidinylisoxazole derivatives |
| 07/06/2006 | CA2591898A1 Mutilin-derivative substituted at position 12 |
| 07/06/2006 | CA2591761A1 Stable particulate pharmaceutical composition of solifenacin or salt thereof |
| 07/06/2006 | CA2591697A1 System and method for power management in mobile units |
| 07/06/2006 | CA2591403A1 Rnai inhibition of serum amyloid a for treatment of glaucoma |
| 07/06/2006 | CA2591294A1 Composition comprising solubilized adapalene with cyclodextrins |
| 07/06/2006 | CA2591259A1 2-(2 or 4-substituted aryloxy)-phenol derivatives as antibacterial agents |
| 07/06/2006 | CA2591232A1 Glycolipids and analogues thereof as antigens for nk t cells |
| 07/06/2006 | CA2591201A1 5-ht7 receptor antagonists |
| 07/06/2006 | CA2591056A1 Stable solid dispersion of a derivative of vinca alkaloid and process for manufacturing it |
| 07/06/2006 | CA2590961A1 [1h-pyrazolo[3,4-d]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-threonine kinase modulators (p70s6k, atk1 and atk2) for the treatment of immunological, inflammatory and proliferative diseases |
| 07/06/2006 | CA2590681A1 N-[(4, 5-diphenyl-3-alkyl-2-thienyl) methyl] amine (amide, sulfonamide, carbamate and urea) derivatives as cannabinoid cb1 receptor antagonists |
| 07/06/2006 | CA2590666A1 5-ht7 receptor antagonists |
| 07/06/2006 | CA2590586A1 Substituted biaryl analogues |
| 07/06/2006 | CA2589283A1 Oxygen-impervious packaging and methods for storing thyroid hormone |
| 07/06/2006 | CA2589052A1 Pharmaceutical formulation of decitabine |
| 07/06/2006 | CA2588941A1 5ht2c receptor modulator compositions and methods of use |
| 07/06/2006 | CA2587475A1 Synergistic effect of amlodipine and atorvastatin on aortic endothelial cell nitric oxide release |
| 07/06/2006 | CA2587388A1 Visco-supplement composition and methods |
| 07/06/2006 | CA2587348A1 Organic compounds |
| 07/06/2006 | CA2586895A1 Injectable or orally deliverable formulations of azetidine derivatives |
| 07/06/2006 | CA2586410A1 Serine amino acid derived prodrugs of propofol, compositions, uses and crystalline forms thereof |
| 07/06/2006 | CA2583244A1 Treatment of graft-versus-host disease and leukemia with beclomethasone dipropionate and prednisone |
| 07/06/2006 | CA2582663A1 Arylpiperazine derivatives and use thereof as 5-ht1a receptor ligands |
| 07/06/2006 | CA2491763A1 Blood glucose control with n-acylated glucosamines |
| 07/05/2006 | EP1676918A2 G-beta-gamma regulated phosphatidylinositol-3' kinase |
| 07/05/2006 | EP1676915A2 Ribozyme therapy for the treatment of proliferative skin diseases |
| 07/05/2006 | EP1676855A2 Prenyl transferase inhibitors |
| 07/05/2006 | EP1676854A1 Polymorphs of a known thiophenecarboxylic acid dodecahydrocyclopenta[a]phenanthrenyl ester |
| 07/05/2006 | EP1676848A1 Polymorphous forms of rifaximin as antibiotics |
| 07/05/2006 | EP1676847A1 Polymorphous forms of rifaximin as antibiotics |
| 07/05/2006 | EP1676846A2 Hydantoin derivatives as MMP inhibitors |
| 07/05/2006 | EP1676845A1 New quinazoline derivatives |
| 07/05/2006 | EP1676844A1 5-HT7 receptor antagonists |
| 07/05/2006 | EP1676843A1 Substituted indole ligands for the ORL-1 receptor |
| 07/05/2006 | EP1676842A1 Nitro-substituted phenyl-piperazine compounds, their preparation and use in medicaments |
| 07/05/2006 | EP1676841A1 Substitited indazolyl sulfonamide and 2,3-dihydro-indolyl sulfonamide compounds, their prepartion and use in medicaments |
| 07/05/2006 | EP1676840A1 5-HT7 Receptor antagonists |
| 07/05/2006 | EP1676839A2 Novel beta crystalline form of perindopril tert-butylamine salt, its preparation method and pharmaceutical compositions containing same |
| 07/05/2006 | EP1676834A1 Fused bicyclic carboxamide derivates for use as CXCR2 inhibitors in the treatment of inflammation |
| 07/05/2006 | EP1676833A1 Propionic acid derivatives useful in the treatment of lipid disorders |
| 07/05/2006 | EP1676590A1 Oncogene therapeutic drug |
| 07/05/2006 | EP1676589A1 Oncogene therapeutic drug |
| 07/05/2006 | EP1676588A1 Polyarginine-modified liposome capable of transferring into nucleus |
| 07/05/2006 | EP1676585A1 Pepsin inhibition by alginates |
| 07/05/2006 | EP1676581A2 Polymer compositions for use in therapy |
| 07/05/2006 | EP1676580A1 Glycyrrhizin high-concentration preparation |
| 07/05/2006 | EP1676579A2 Use of sub-antimicrobial tetracyclines for treating ocular rosacea |
| 07/05/2006 | EP1676578A1 Method of stabilizing diarylvinylene compound |
| 07/05/2006 | EP1676577A1 Compositions for the treatment of cancer comprising a topoisomerase inhibitor and thalidomide |
| 07/05/2006 | EP1676576A1 Combinations comprising camptothecin and their use for the treatment of neoplastic diseases |
| 07/05/2006 | EP1676575A2 Mucin production inhibitor |
| 07/05/2006 | EP1676574A2 Methods for promoting survival of transplanted tissues and cells |
| 07/05/2006 | EP1676573A1 Phamaceutical composition comprising a 2,5-dihydroxybenzenesulfonic-compound, a potassium ion channel modulator and a phosphodiesterase type 5 inhibitor |
| 07/05/2006 | EP1676572A1 Remedy for autoimmune diseases |
| 07/05/2006 | EP1676571A1 Composition comprising at least one isoflavonoid and carnitine and/ or at least one acyl-carnitine |
| 07/05/2006 | EP1676570A1 Topical pharmaceutical compositions comprising L-arginine and uses thereof |
| 07/05/2006 | EP1676551A2 Treatment of hepatitis C using hyperthermia |
| 07/05/2006 | EP1676488A2 Compositions and methods for body weight management |
| 07/05/2006 | EP1676132A1 System and method for the treatment of cancer, including cancers of the central nervous system |